ARTICLE | Clinical News
FDA approves Bayer's recombinant Factor VIII for hemophilia A
August 31, 2018 6:02 PM UTC
FDA approved a BLA from Bayer AG (Xetra:BAYN) for Jivi damoctocog alfa pegol (BAY94-9027) to treat hemophilia A in patients ages 12 and older. Bayer told BioCentury the product will be launched the first week of September and at a price competitive to other hemophilia drugs in its class.
Jivi is a pegylated recombinant form of human Factor VIII (rFVIII)...
BCIQ Company Profiles
BCIQ Target Profiles